NP001, a pH‐adjusted intravenous formulation of sodium chlorite, hypothesized to regulate inflammation through reduction of nuclear factor‐κB and inhibition of interleukin (IL)‐1β within monocytes/macrophages, was not found to be efficacious in clinical outcome measures, but, in an emerging effort to examine biomarkers, a subset of ALS participants who had slowing of progression (responders) were also noted to have elevated IL‐18, IL‐6, interferon gamma, and C‐reactive protein (CRP) levels when compared to nonresponders.34, 35. The gene discussed is CRP; the disease is amyotrophic lateral sclerosis.